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Immunopathology of renal allograft rejection analyzed with monoclo-
nal antibodies to mononuclear cell markers. The composition of the
mononuclear cell infiltrate in rejecting renal allografts was determined
on 96 renal biopsies and 22 nephrectomy specimens by the use of
monoclonal antibodies to mononuclear cell surface markers and an
indirect immunoperoxidase staining technique. During rejection the
composition of the infiltrate was heterogeneous, with T cells (Ti 1),
monocytes (OKM1) and HLA-DR expressing mononuclear cells the
most frequent sub-populations. B cells (BI) and activated T cells,
identified by OKT1O, were always in the minority. The T cells infiltrate
usually included the helper/inducer (T4) and cytotoxic (T8) subclasses,
which suggests that both may contribute to the mediation of rejection.
Whether T4 or T8 predominated in the graft did not relate to the ratio of
T4:T8 in blood, the HLA A, B or DR incompatibilities of the graft, or
the immunosuppressive used. The frequency of Til, T4, T8, HLA-DR
positive cells and monocytes, but not B cells, increased with the
severity of rejection and was similar in biopsies from patients immuno-
suppressed with Cyclosporine (CSA) to those given a combination of
azathioprine, prednisone and antilymphocyte globulin (AZA). Severe
rejection episodes which did not respond to treatment with corticoster-
oids were more often characterized by a predominance of T8 over T4
cells and T cells infiltrating the glomeruli. In grafts with evidence of
cellular rejection, renal tubular cells were shown to have a marked
increase in their expression of HLA-DR antigens compared to normal
kidneys or grafts with minimal rejection. The expression of HLA-DR
antigens on graft tubular cells correlated with the presence of T cells in
the interstitium and the severity of rejection, except for moderate
rejection in CSA treated biopsies, in which HLA-DR expression was
lower than in AZA biopsies. These immunopathological studies have
demonstrated that a variety of potential effector cells exist within the
graft, and several features have been identified which may assist in
assessing the prognosis of the rejection episode.
The precise diagnosis of renal allograft rejection is dependent
upon the identification of well described changes seen by light
microscopy in biopsies [1—3]. The morphology of the rejection
process is heterogeneous, which reflects the fact that allograft
rejection can be mediated by a variety of immune mechanisms,
including T lymphocytes or antibody, either directly or through
antibody dependent, cell mediated cytotoxicity and natural
killer cells [4—6]. T lymphocytes have been identified as the
principal effector response [7]. More recently it has been shown
that T lymphocytes of the helper/inducer subclass, as well as
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cytotoxic T lymphocytes, can mediate allograft destruction
[8—13]. Until recently it has been thought that helper/inducer
cells mediate rejection via activation of macrophages in a
classical delayed-type hypersensitivity response, and that
cytotoxic T cells acted directly on graft cells. However, there is
now evidence that both subclasses of cells can mediate both
delayed-type hypersensitivity and direct cytotoxic effects [14].
It has also been suggested that helper/inducer cells only act
against cells expressing class II major histocompatibility com-
plex (MHC) antigens and cytotoxic cells against those express-
ing the relevant class I MHC antigens (14, 15). The relative
importance of these two effector mechanisms in the mediation
of kidney allograft rejection remains unknown. It is possible
that the presence of different subclasses of T cells in renal
allografts may indicate that different effector mechanisms are
operating and that these mechanisms may have different re-
sponses to anti-rejection therapy.
Monoclonal antibodies, which can identify mononuclear cell
subpopulations, including the different subsets ofT cells, have
been used with immunostaining techniques to confirm that
during acute renal allograft rejection the cellular infiltrate is
heterogeneous [16—19]. In this study commercially available
monoclonal antibodies and indirect immunoperoxidase staining
were used to identify the mononuclear cell infiltrate in renal
transplant biopsies and nephrectomy specimens. T cells, B
cells, helper/inducer T cells, cytotoxic T cells, activated T cells
and monocytes have been identified, using the reagents listed in
Table 1 [20—26] (Til, T4, T8, Bl, Il, Coulter Electronics Inc.,
Hialeah, New Jersey, USA; OKT1O and OKM1, Ortho Phar-
maceutical Co., Raritan, New Jersey, USA). As we have
previously observed that renal tubular cells express HLA-DR
antigens during severe rejection episodes [27], the expression of
these antigens by cells within biopsies was also examined, This
report is an extension of previous studies where we have
reported on the immunopathology of rejection [19, 27]. How-
ever, in this study a larger number of biopsies was evaluated
and it was possible to analyze the diagnostic usefulness of
identification of the cellular infiltrate in determining the sever-
ity, prognosis or reversibility of the rejection episode, and also
a comparison of the patterns of cellular infiltrate in kidneys
from patients with different HLA incompatibilities and treated
with either Cyclosporine (CSA) or azathioprine, prednisone and
antilymphocyte globulin (AZA).
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Antibody Concentration Specificity Reference
Ti! 1:40 Pan T cell [20]
T4 1:20 Helper/inducer T [21]
T8 1:80 Cytotoxic/suppressor T [221
OKT1O
BI
1:80
1:10
Activated T, myeloid
precursors
B cells
[22]
[24]
OKMI 1:160 Monocytes [23]
12
Neuraminidase
1:160
1:20
HLA-DR non-poly-
morphic structure
Influenza neuraminidase
[251
[26]
Biopsies
grade
Severity of rejection
Nephrec-
Minimal Moderate Severe tomy
Treatment group CSA AZA CSA AZA CSA AZA CSA AZA
Specimens 18 5 30 17 15 1! 10 12
Patients 15 5 25 16 8 11 10 12
Time since transplant
Less than 2 weeks 5 3 6 1 5 5 1 3
15 days to 13 weeks 4 1 14 8 10 3 5 5
More than 13 weeks 8 1 10 8 0 3 4 4
Graft function
Post-trans. oliguria 7 3 12 1 11 6 — —
Acute deterioration 9 2 17 15 5 5 — —
Chronic deterioration 2 0 1 1 0 0 — —
Rejection treatment
Less than 7 days
prior 9 0 9 6 6 7 6 6
After biopsy 6 2 17 15 14 11 — —
Course of Rejection
Good recovery 6 2 6 12 5 2 — —
Progressed to
nephrectomy 2 1 2 5 8 7 — —
Days to nephrectomy
Median — 30 — 180 36 9 — —
Minimum 40 — —100 3 17 7 — —
Maximum 500 — —180 360 72 39 — —
Materials and Methods
Source of clinical material
Twenty two nephrectomy and 96 biopsy specimens were
obtained from a total of 76 renal transplant patients who had
consented to enter a randomized clinical trial that compared the
efficacy of treatment with CSA as the sole immunosuppressant,
to that with AZA. Details of patient management and clinical
indications for performance of a biopsy or nephrectomy have
been previously reported [3, 28]. Briefly, renal biopsies were
performed every seven to ten days in the post-transplant
oliguric phase or to diagnose the cause of deterioration in renal
function. Biopsies were only performed when required to assist
in the clinical management of the patient and after written
consent was obtained. Clinical details of patients who had
nephrectomy and biopsy specimens are shown in Table 2. HLA
A, B, and DR typing was performed by the Tissue Typing
Laboratory (N.S.W. Red Cross Blood Transfusion Service,
Sydney, N.S.W. Australia) as described [29]. Therapy for acute
rejection episodes was I g of methyl prednisone (Upjohn, West
Ryde, Australia) given i.v. as a single bolus on three consecu-
tive days. A good response to therapy was recorded if the
serum creatinine fell and graft function remained stable for
seven days. Failed response to therapy was recorded if the
serum creatinine continued to rise in spite of anti-rejection
therapy and did not return to its pre-rejection nadir.
Processing of renal biopsy tissue
Renal biopsy or nephrectomy material was divided and one
part fixed in 5% buffered formalin and embedded in paraffin for
routine light microscopic examination. The remainder was
embedded in Tissue Tek II mounting medium and snap frozen
in liquid nitrogen for immunoperoxidase staining, as previously
described [19, 27]. Light microscopic sections were assessed
for evidence of rejection, which was graded as severe, moder-
ate or minimal, on criteria which have been previously de-
scribed [2, 31. Briefly, mild rejection was diagnosed when only
local or sparse cellular infiltrate of the interstitium was present
without vascular or glomerular lesions. In moderate rejection,
there was more intense and diffuse cellular infiltrate with some
vascular damage present, such as mild intimal proliferation.
Severe rejection had changes as in moderate rejection, but they
were more extensive and diffuse with more marked vascular
changes, interstitial hemorrhage and areas of necrosis. The
frequency of specimens in each category is listed in Table 2.
Immunoperoxidase stains
Frozen sections six microns in thickness were cut onto
gelatinized slides, air dried and fixed in acetone at room
temperature for ten mm. before being washed in phosphate
buffered saline (PBS) for five mm. Sections were then incubated
for 30 mm. with 25 d of monoclonal antibody diluted in 5% AB
serum in PBS. The panel of monoclonal antibodies used is
shown in Table 1. Slides were washed in PBS then incubated for
30 mm. with 25 l of rabbit antiserum to mouse immunoglobulin
conjugated with horseradish peroxidase (Dako AJG, Copenha-
gen, Denmark), diluted 1:20 in 5% AB serum. After being
washed in PBS, the sections were exposed for 10 mm. to 1
mg/mI diaminobenzidine tetrahydrochloride (Sigma) and 0.01%
H202 and 0.3% sodium azide in 0.05 M Tris buffer pH 7.6.
Sections were counterstained in Mayer's hematoxylin, dehy-
drated and mounted.
Assessment of peroxidase stained sections
hnmunoperoxidase-stained sections were assessed by two of
us (GAB & BMH) without knowledge of the clinical or patho-
logical diagnosis, and each section was scored in a semi-
quantitative manner. This method is similar to that used to
assess severity of light microscopic changes in transplant biop-
sies and gave reproducible results with a high concordance
between observers. The score represented an assessment of the
whole section, which was at least a 3 mm length of the needle
biopsy specimen. The mononuclear cell interstitial infiltrate was
scored as described previously [191: + + +, when mononuclear
cells surrounded each tubule and were present both in the
interstitium and between tubular cells, and when the whole
tissue examined was uniformly infiltrated; + +, when there
were cells surrounding tubules but few or no cells between
tubular cells, and when the infiltrate was not distributed uni-
formly; +, when cells were sparsely scattered through the
Table 1. Monoclonal antibodies used for indirect immunoperoxidase
stains of renal biopsies
Table 2. Clinical data of patients at time of biopsy or nephrectomy
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interstitium and many tubules had no cells nearby; —, indicated
that cells were absent or present only occasionally. The number
of stained mononuclear cells infiltrating glomeruli was counted,
and the results from 10 glomeruli were averaged. The pheno-
type of cells in perivascular inifitrates attached to the vascular
endothelium was noted.
The extent of renal tubular cell staining for HLA-DR antigen
was assessed as previously described [27]. The distribution and
intensity of tubular staining for DR was graded: ++ +, intense
staining of all tubular cells, including proximal tubule, distal
tubule, loop of Henle, and collecting duct tubular cells; ++,
moderate to intense staining of some tubular cells, proximal
tubules were usually stained, and staining of distal tubules, loop
of Henle and collecting ducts was variable; +, moderate tubular
cell staining, usually confined to proximal tubules; —, no
increased tubular staining, compared to non-transplant control
kidney sections.
Proximal convoluted tubules were distinguished from distal
convoluted tubules by their larger diameter and more columnar
appearance. In biopsies with severe rejection or tubular necro-
sis, this distinction was often not possible.
Reproducible staining of renal biopsy material was obtained,
using the indirect immunoperoxidase technique. To optimize
conditions, we used sections from normal spleens as positive
controls and biopsy specimens from non-transplanted kidneys
with no mononuclear cell infiltrate as negative controls. The
latter had been performed to investigate hematuria and protein-
uria (17 were normal to light microscopy and 9 had mild
mesangial disease). In normal kidneys, only occasional cells in
capillaries and vessels stained with Ti!, T4, T8, OKT1O, B, or
0KM 1. Staining with 12 was prominent on capillary endothe-
hum and dendritic cells in the interstitial space, and the mesan-
gial cells and capillary endothelium of the glomeruli. Proximal
tubular cells showed no evidence of membrane staining with 12
but had a faint diffuse staining pattern concentrated at the base
of the cell. There was no staining of distal tubules, collecting
ducts and loop of Henle.
Control sections were included in the staining of each spec-
imen and were incubated with a mouse monoclonal antibody to
influenza neuraminidase. These had no membrane or cytoplas-
mic staining of cells, confirming that the technique used iden-
tified the specific epitopes of the monoclonal antibody used
rather than non-specific or FC receptor staining.
Identification of peripheral blood lymphocyte subsets
Immunofluorescent staining of peripheral blood lymphocytes
using OKT4, OKT8 and OKT3 (Ortho Diagnostics, Raritan,
New Jersey, USA) was performed as described by Cosimi et al
[30]. Fluorescent labelled sheep anti-mouse Ig (Silenus Labo-
ratories, Dandenong, Australia) was used as the second phase
reagent. Fluorescent cells were counted on a Spectrum III
Cytofluorograph (Ortho Instruments, Westwood, Massachu-
setts, USA) as described [30]. There was no difference in the
percentage of lymphocytes labelled by OKT4 and T4 (mean
SD, 36.6 7.7% vs. 37.2 8.1%, P = 0.52 in paired Student's
t test) or by OKT8 and T8 (30.1 14.4% vs. 27.9 15.0%,P =
0.20), when these reagents were compared in blood samples
from eight renal transplant recipients.
Statistical Analysis
Analysis of the ranked data was by Brandt-Snedecor 4 x 2
contingency table analysis with the ranks —' +, + + and + + +
corresponding to the four rows of the contigency table. Using
this technique, two frequency histograms could be compared to
give a x2 with three degrees of freedom. Groups of numerical
data were compared during Student's t test.
Results
T lymphocytes were the most numerous infiltrating cells in 84
of the 96 biopsies, and in 14 of the 22 nephrectomies.
Monocytes were the next most numerous population of infil-
trating cells, and were the most numerous cells in the infiltrate
in seven nephrectomy and six of the biopsy specimens. B
lymphocytes were observed in a minority of the biopsies and
were never seen to comprise a major component of the infil-
trate. T4 lymphocytes were the major T cell subset in five
nephrectomy and 27 biopsy specimens. T8 lymphocytes were
the major subset in six nephrectomy and 18 biopsy specimens.
All other specimens had a similar frequency of T4 and T8 cells.
OKT1O cells and B lymphocytes represented the minority of
cells in all specimens. HLA-DR was identified on the majority
of infiltrating cells and there was increased expression of
HLA-DR on tubular cells during rejection.
T and B lymphocytes in infiltrates
T lymphocytes preponderated over B lymphocytes in all
specimens. Even in severe cases of rejection, few B lympho-
cytes were present. The T cell infiltrate was widely scattered
throughout the interstitium, between tubular cells and in clus-
ters surrounding medium sized vessels. The extent of the
infiltrate depended upon the severity of rejection, with only
scattered foci of cells in the interstitium in cases of mild
rejection. Foci of T cells were found around vessels and some
glomeruhi; these were often seen in mild to moderate rejection,
when the interstitial infiltrate was sparse or patchy, as well as in
severe rejection and nephrectomy specimens. In biopsies with
moderate or severe rejection and nephrectomy specimens, T
cells, but not B cells, were seen lining the intima and infiltrating
the adventitia but were not in the media of medium-sized
vessels.
B lymphocytes were found as focal infiltrates, usually asso-
ciated with perivascular T lymphocyte infiltrates. B cells were
infrequent, or absent in the interstitial inifitrate, between tubu-
lar cells, on the intima of vessels or in glomeruli. Many biopsies
with severe rejection had virtually no B cell infiltrate.
Frequency histograms of the incidence of T and B lympho-
cytes are shown in Figure 1. Comparison of the CSA and AZA
therapy groups with the same histological grade of rejection
showed no significant difference between the two groups in the
extent of infiltration with either T or B lymphocytes. Pooled
results of the CSA and AZA data showed there was a significant
increase in the extent of T lymphocyte infiltrate from minimal to
moderate rejection (P < 0.0005) and from moderate to severe
rejection (P = 0.04). There was no significant difference in the
extent of T cell infiltration in nephrectomies compared to the
severe biopsy group. T lymphocytes were observed infiltrating
the glomerulus (Fig. 2) and there were increasing numbers of
glomerular T lymphocytes with increasing severity of rejection
Immunopathology of renal allograft rejection 711
LL
-++H4+ —+4+444-
CSA AZA
Fig. 1. Histograms showing the number of specimens that had a
different extent of infiltrate. Data is shown for extent of infiltrate,
identified by Ti 1 or the Bi monoclonal antibodies. Results were divided
so that patients treated with Cyclosporine (CSA) were compared to a
combination of azathioprine, predmsone and antilymphocyte globulin
(AZA). Extent of infiltrate is scored from — to + + + as described in
Materials and Methods. T lymphocytes predominate in all specimens
observed.
Fig. 2. Photomicrograph of a renal allograft biopsy showing severe
acute cellular rejection. An indirect immunoperoxidase stain using
monoclonal antibody TI! identifies T lymphocytes which have a dark
rim of stain. T lymphocytes are seen infiltrating the glomerulus, as well
as scattered in a diffuse penglomerular infiltrate.
(Fig. 3). There were significantly more glomerular T cells in
biopsies with severe compared to moderate rejection (P =
0.002), and between nephrectomy and severe biopsies (P =
0.05). No B cells were found in glomeruli of transplant kidneys.
No T or B cells were found in the glomeruli of control
non-transplant kidneys.
Helper/inducer (T4) and cytotoxic/suppressor (T8) T
lymphocyte subsets
Both T4 and T8 cells were present in large numbers in all
biopsies with moderate and severe rejection. However, their
• U
. U
:!I iTi .1TLT
Fig. 3. Intensiiy of glomerular T lymphocyte infiltrate with severity of
rejection. Glomerular T lymphocytes were counted and the average
number of T cells in 10 glomeruli is shown. The extent of glomerular T
cell infiltrate increases with severity of rejection. Symbols are: U
CSA-treated patients; • AZA-treated patients; 0 Non-transplant pa-
tients. Error bars show mean SD.
concentrated in the focal infiltrates, often in a perivascular or
periglomerular location. They were usually the minority of cells
in the interstitium, and were less often found between tubular
cells, in the glomeruli, or attached to the intima of vessels. In
some biopsies, a diffuse staining with T4 was seen which could
not be removed with repeated washing, and was present in
sections that gave clear membrane staining with other reagents.
This widespread staining may represent a release of the T4
epitope into the plasma. The T8 cells had a much more
widespread distribution. They were the preponderant mononu-
clear cells in the interstitium, between tubular cells, in
glomeruli and on the intima of vessels, but were the minority in
focal cellular infiltrates.
Frequency histograms of the extent of infiltration with T
lymphocyte subsets is shown in Figure 4. There was an increase
in the inifitrate of both T4 and T8 cells with increasing severity
of rejection. Comparison of the AZA and CSA treatment groups
with similar histological grades of rejection showed a prepon-
derance of T4 compared to T8 only in biopsies with moderate
rejection in the CSA treated patients. In neither treatment
group did T8 predominate over T4. No difference in the
incidence of either subset was seen in the AZA or the other
CSA biopsy groups. No significant differences in the infiltrate of
T4 compared to T8 cells was observed when the data from both
treatment groups were pooled.
In biopsies with moderate or severe rejection, both T4 and T8
cells were found in glomeruli and along the intima of vessels. In
the glomeruli, T4 cells predominated over T8 in only five of the
49 biopsies that had a T cell inifitrate, compared to the predom-
inance of T8 over T4 in 19 biopsies. Both cell types were found
in the capillary loops and mesangium of the glomeruli.
Relationship of T4, T8 ratios in blood and graft
Thirty-three biopsies with moderate or severe rejection had
peripheral blood T4:T8 ratios performed on the day of biopsy.
The blood ratio showed no correlation with the relative pre-
T11-T Lymphocytes B1-B Lymphocytes
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Fig. 4. Histograms showing the number of specimens (hot had a
different extent of infiltrate. Data compares T4 and T8 monoclonal
antibodies and patients treated with CSA or AZA. Extent of infiltrate is
scored from to +++ as described in Materials and Methods. With
comparable severity of rejection, a similar extent of infiltrate for each
subset was observed, except when biopsies from CSA patients with
moderate rejection were observed. These biopsies showed significantly
greater T4 cells than T8 cells (P = 0.05, Brandt-Snedecor contingency
table analysis).
dominance of T4 or T8 in the rejecting graft, in that the blood
T4:T8 ratio exceeded one for seven of eight biopsies in which
T8 cells were present in greater numbers than T4, and for 16 of
19 where the frequency of T4 and T8 in the biopsy was similar
(Fig. 5). Thus there appeared to be a relatively greater influx of
T8 than T4 cells from blood into the graft in the majority of
cases. The blood T4-T8 ratio exceeded one in five of the six
biopsies where T4 predominated over T8.
Relationship of T4 and T8 infiltrate to HLA match
If T4 cells act against class II MHC antigens and T8 against
class I MHC antigens, differences in the infiltrate may be
expected in grafts matched for one class of MHC antigens and
not the other. In 26 biopsies, with severe or moderate rejection
from 19 patients with no HLA-DR mismatches but one or more
HLA-A or B mismatches, there was an infiltrate of T4 in 23 and
of T8 in 20 specimens. In the six biopsies from five patients with
no mismatches for HLA-A B, there was a T4 infiltrate in five,
and a T8 infiltrate in two. The latter two also had no ElLA-DR
mismatch. These results showed that no significant preponder-
ance of one subset of T cells was demonstrable in biopsies from
grafts with different HLA matches. There were also no signif-
icant differences in the pattern of infiltrate of T cells, B cells,
OKT1O cells or monocytes with different HLA mismatches.
Lymphocyte activation markers
In an attempt to assess the proportion of the mononuclear cell
infiltrate which was activated, two monoclonal antibodies were
used. 12, which recognizes HLA-DR, reacts with T cells when
T4>TB T4=T8 T4cT8
Biopsy, 4:8 ratio
Fig. 5. Comporison of the ratio of T4 lymphocytes to TB lymphocytes in
blood and graft with oil samples taken on the same day. Blood T4:T8
ratios are grouped according to whether the corresponding biopsy had
a preponderance of the T4 lymphocytes. T4 and T8 lymphocytes were
present in equal numbers; TS lymphocytes were preponderant. No
significant difference was seen in the blood T4:T8 ratio between any of
the groups, indicating that blood T4:T8 ratio does not reflect graft T4:T8
ratio.
they are activated, and also with normal B cells, monocytes and
macrophages. 12 not only stained the majority of infiltrating
mononuclear cells, including nearly all the cells in foci, but also
stained renal tubular cells in rejection. Comparison of the AZA
and CSA treatment groups showed no difference in the degree
of expression of ElLA-DR on infiltrating mononuclear cells.
When AZA and CSA data were pooled, there was a significant
increase in interstitial HLA-DR from minimal to moderate (P <
0.001), and from moderate to severe (P 0.05), but there was
no increase from severe biopsies compared to nephrectomy
specimens (Table 3).
OKT1O identified a proportion of, but not all activated T
cells, plasma cells and null cells. OKT1O-staining lymphocytes
were found in small foci of five to ten cells which were scattered
in the interstitium. They were not found in the large foci, in
vessel walls or in the glomeruli. There was no difference in the
incidence of OKTIO when the AZA and CSA treatment groups
were compared. Analysis of pooled AZA and CSA data showed
a significant increase in OKT1O lymphocytes from minimal to
moderate (P 0.05) and an upward trend in the nephrectomy
compared to the severe biopsy group (P = 0.08). However,
many biopsies with moderate and severe rejection or nephrec-
tomy specimens had no infiltrate of OKTIO cells (Table 3).
Monocyte infiltrate
Monocytes were defined by the monoclonal antibody 0KM 1,
which reacts with all peripheral blood monocytes [23] but which
does not identify all infiltrating monocytes and macrophages
[17]. Monocytes were found to be scattered through the inter-
stitium, in glomcruli and the intima of vessels. When the CSA
and AZA treatment groups were analyzed separately, in the
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Table 3. Infiltrate in kidney allografts
Type of cellular infiltrate
.
Severity of
rejection Total
OKM1 (%) OKT10, % Interstitial I2, %
— + ++ +++ P — + ++ +++ P — + ++ +++ P
Nephrectomy 22 27 32 9 32 41 32 27 0 0 19 33 48
0.025 0.08 NSD
Severe 26 58 17 21 4 71 9 5 5 0 21 62 17
NSD NSD 0.05
Moderate 47 60 30 10 0 73 22 5 0 9 45 32 14
0.05 0.05 0.001
Minimal 23 90 0 10 0 100 0 0 0 65 31 4 0
Percentage of specimens in each rejection category, showing extent of cellular infiltrate graded from — (minimal evidence of infiltrate) to + + +
(extensive infiltrate). Biopsies were graded as minimal, moderate or severe rejection on the basis of conventional histologic criteria. Cell
populations examined were monocytes (OKM1), activated lymphocytes (OKT1O) and HLA-DR positive interstitial influence (interstitial 12). The
percentage of specimens showing moderate or heavy infiltrate increased with severity of rejection.
Table 4. Comparison of infiltrates of T4 and T8 cells on the basis of subsequent response of rejection to corticosteroid therapy
Severity of
rejection
Response to
cortico-
steroids Total — +
T4, %
+ + + + +
Significance
P — +
T8, %
++ + + +
Severe
Yes
No
7
18
0
11
29
50
42
39
29
0
0.09
0.09 0.01
0.5
57
0
29
56
14
33
0
11
Moderate + Yes 33 12 48 33 7 0.15 30 33 37 0
Severe
No 21 20 47 33 0
0.6 0.07
0.4 5 52 33 10
AZA group but not the CSA, there was a significant increase in
the incidence of monocytes in nephrectomies compared to the
severe rejection group (P = 0.04). Pooled data on CSA and
AZA (Table 3) showed there was a significant increase in the
nephrectomized group compared to the severe biopsy group (P
= 0.025), which was due mainly to the increase in the AZA
treatment group. There were further increases from minimal to
moderate and to severe. The increase in monocytes from
minimal to moderate was the only significant difference (P =
0.05).
Difference in biopsies which did or did not respond to
rejection treatment with corticosteroids
Results of biopsies graded as moderate or severe from
patients who had been given corticosteroid therapy immedi-
ately subsequent to biopsy, were grouped according to whether
they had responded to therapy with return to stable renal
function (N = 35), or whether they had not responded to
therapy (N = 21). There was a tendency for T8 lymphocytes to
be more numerous in biopsies from patients who did not
respond to therapy (P = 0.07). Analysis of severe rejection
biopsies alone showed a significant (P = 0.01) increase in T8
lymphocytes in those patients who did not respond to treatment(N = 18), compared to those patients whose rejection did
respond to treatment (N = 7) (Table 4). There was a cone-
sponding trend to a lesser degree of T4 lymphocyte infiltrate in
patients who did not respond to treatment, compared to re-
sponders (P = 0.09) (Table 4). When the severe and moderate
groups were pooled and the T4 and T8 subsets were compared
in each patient, it was found that the T4 subset predominated in
12 of 35 responders, whereas the T8 subset predominated in
only six. In the patients with non-response to rejection treat-
ment, T8 predominated in seven of 21 patients, whereas the T4
predominated in five patients. Although there is an overlap
between groups, the data shows that if there is no T8 cell
infiltrate, the rejection should respond to corticosteroids. If
there is intense (+ + +) T8 cell inifitrate, there is a high chance
that rejection will not respond to corticosteroid therapy.
Glomerular T cells in biopsies from patients who responded to
therapy (N = 21) showed significantly fewer glomerular T cells
than those who did not respond (N 13) (P = 0.05, Fig. 6).
Effect of time after transplant on mononuclear cell infiltrate
Biopsy and nephrectomy findings were grouped into three
classes according to time elapsed since transplant: early, within
two weeks of transplant (N = 29); mid, 15 days to 13 weeks post
transplant (N = 50);or late, more than 13 weeks post transplant(N = 38). The only significant differences were the presence of
more T lymphocytes (P = 0.001) and OKT1O cells (P = 0.03) in
the mid group than the early biopsies. However, these differ-
ences were not significant when the biopsies with only moder-
ate and severe rejection were analyzed. In early rejection
episodes, T4 cells exceeded T8 cells in nine biopsies, whereas
T8 cells exceeded T4 cells in four biopsies. In the mid-group T4
cells were the minority in 12 biopsies and the majority of the
infiltrate in 10 biopsies. The pattern of T4 cells versus T8 cells
in the late group was similar to the early group. There were
more T8 lymphocytes in the mid-group than the early group (P
= 0.03), but not the late group.
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Yes No
Fig. 6. Intensity of glomerular T lymphocyte infiltrate with response to
steroid therapy. Pooled data for AZA and CSA showed a significant
increase in the number of glomerular T lymphocytes in those patients
who did not respond to steroid therapy (Student's t test). Symbols are:
U CSA-treated patients; and, • AZA.treated patients.
Change in infiltrate from biopsy to nephrectomy
Eleven of the 22 nephrectomy specimens had had a biopsy in
the preceding four weeks. The only significant difference be-
tween these paired samples was that monocytes were more
frequent in the nephrectomy specimens (P = 0.03).
Expression of HLA-DR by renal tubular cells
The extent of expression of HLA-DR by tubular cells in-
creased with the severity of rejection (Table 5). The severe
rejection biopsies had more HLA-DR antigen expression than
the moderate rejection biopsies (P = 0.04) and the moderate
biopsies showed more than the minimal (P =0.003). However,
nephrectomies did not show significantly greater staining for
tubular HLA-DR than did the biopsies with severe rejection.
There was increased expression of HLA-DR on tubular cells
with increasing severity of rejection in both CSA and AZA
treatment groups. The biopsies with moderate rejection in the
CSA treatment patients showed significantly less staining than
AZA with moderate rejection (P = 0.025). To determine
whether the lesser expression of tubular HLA-DR in moderate
CSA biopsies was due to biopsies having CSA nephrotoxicity,
rather than rejection, we divided these biopsies into those
whose clinical course suggested that they had concomitant CSA
nephrotoxicity (N = 11) and those who had no evidence of
nephrotoxicity (N 5). There was no difference in expression
of HLA-DR on the tubular cells (P =0.4). Biopsies with severe
and moderate rejection showed no difference in the degree of
HLA-DR expression between groups with or those without
HLA-DR incompatibilities. In all but two of the 59 specimens
with marked HLA-DR expression (+ + + or + +) on tubular
cells there was an associated interstitial T cell infiltrate. These
two included a patient with chronic vascular rejection and
another who had been successfully treated for acute cellular
rejection five days prior to biopsy. A significant T4 and T8
infiltrate was also present in the majority of biopsies, with
marked HLA-DR expression on tubular cells. However, 13 of
the 59 biopsies had an infiltrate of only T4 and 9 of 59 only had
T8.
DiscussIon
These studies confirm the heterogeneous composition of the
mononuclear cell infiltrate in rejecting allografts which has been
previously described in animal models, as well as in clinical
organ transplant material [4—12]. Our studies also confirm that T
cells are the principal infiltrating cell [4—13], and that there is
also a large monocytic cell accumulation in rejecting tissue [7,
31]. The intensity of the infiltrate of these two populations
increases with increasing severity of rejection and is greatest in
nephrectomy specimens with irreversible rejection. These find-
• ings parallel the standard histopathological analysis in which a
poor prognosis is determined by the intensity of the cellular
infiltrate, the presence of interstitial hemorrhage, vascular
rejection and glomerulitis [1—3]. Our studies confirm that al-
though severe irreversible rejection usually has an intense
interstitial infiltrate, this feature is also seen in kidneys with
rejection that is reversible with corticosteroid treatment. We
observed that in irreversible rejection, the infiltrate tended to
have a predominance of T8 over T4 cells compared to biopsies
with reversible rejection that had a predominance of T4 cells. In
the mild and moderate rejection episodes and those occurring in
the first two weeks after transplant, which were easily reversed
with corticosteroid therapy, the cellular infiltrate was concen-
trated around vessels, rather than in the interstitium, and that
this infiltrate was predominantly T4. This finding concurs with
that of Tufveson et al [32] in nephrectomy transplant specimens
who also reported that T4 predominates in the mononuclear cell
infiltrate and is concentrated around vessels. However, our
findings do not support Von Willebrand's finding that their
patients who had fine needle aspirate biopsies in which T4
predominated did not respond to corticosteroids [33]. This may
be because aspirate samples do not totally reflect the diffuse
infiltrate in the graft. In severe rejection which did not respond
to steroids, and rejection occurring later than two weeks after
transplant, the perivascular infiltrate of T4 cells was found, but
in addition there was an interstitial infiltrate in which T8 cells
predominated in a small series of biopsies. Severe and cortico-
steroid resistant rejection was also accompanied by infiltrates of
T cells in glomeruli and along vascular endothelium. Both
rejection glomerulitis and vascular rejection have been assumed
to be humoral, rather than cell mediated [1, 2]. The finding of T
cells in these sites raises the possibilty that T cell mediated
effector mechanisms also contribute to these changes. Both T4
and T8 cells were found in the vascular interstitium and in
glomeruli, where they were localized in the glomerular capillary
walls, as well as the mesangium. Glomerular T cell infiltrates
increased with the severity of rejection, suggesting that they
may simply be a manifestation of a more widespread inifitrate of
all areas of the allograft. We propose that a widespread inter-
stitial infiltrate of T8 cells and glomerular T cell infiltrate are
poor prognostic signs, which could be used to complement the
classical light microscopic changes in the establishment of a
poor prognosis and response to corticosteroid therapy. It re-
mains to be evaluated whether the use of these parameters to
identify patients with a high risk of failing to respond to
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Table 5. HLA-DR expression on renal tubular cells
Severity of
rejection Total
CSA
—
treated
+
intensity
+ +
12, %
+ + +
CSAvs.
AZA
significance Total
AZA
—
treated
+
intensity
+ +
12, %
+ + ÷
SignificanceP
Nephrectomy
Severe
Moderate
Minimal
10
15
28
18
0
0
14%
50%
10%
13%
36%
33%
10%
27%
28%
11%
80%
60%
21%
6%
NSD
NSD
0.025
NSD
11
10
16
5
0
0
0
40%
0
0
6%
0
18%
20%
38%
20%
82%
80%
56%
40%
06
OO3
0003
HLA-DR antigen expression by renal tubular cells in biopsies and nephrectomies of patients treated with CSA, compared to patients treated with
AZA. Extent of HLA-DR expression by tubular cells is rated from — (no expression) to + + + (most tubular cells express HLA-DR). Percentage
of specimens at each level of expression is shown. Extent of HLA-DR expression for pooled CSA and AZA results showed significant increases
with increasing severity of rejection. Comparison of CSA and AZA groups showed no difference in tubular HLA-DR antigen expression with
minimal or with severe rejection, but a significant reduction in the CSA group with moderate rejection.
corticosteroid therapy can be used to institute alternate anti-
rejection treatment.
These studies did not help to resolve the controversy over the
relative roles played by cytotoxic T cells and T cells of the
helper/inducer subclass in the mediation of rejection [6, 8—13].
In vitro models of the alloimmune response identified the
cytotoxic T cell as the principal effector T cell [34, 35].
However, adoptive transfer experiments in rodents have con-
tradicted the in vitro models of the alloimmune response by
demonstrating that helper/inducer cells, rather than cytotoxic T
cells, effect graft rejection [8—10]. More recent adoptive transfer
studies have confirmed that cytotoxic T cells can also effect
rejection in vivo [11, 12]. Whatever the relative importance of
these two responses in the mediation of graft destruction, our
studies show that during rejection, a large number of cells of
both phenotypes are present within the graft, thus leaving open
the possibility that tissue destruction is mediated by effector
responses from both subsets of cells. The T8 subpopulation
increases in rejection episodes that occur later than two weeks
compared to immediate post-transplant episodes. Comparison
of blood T4:T8 ratio to the corresponding T4:T8 ratio in the
graft suggests there is usually a relatively greater influx of T8
cells. The preponderance of 18 cells in severe rejection epi-
sodes appears to be a poor prognostic sign and this may be due
to T8 mediated responses being more resistant to the effects of
corticosteroids than T4 mediated responses. Support for this
possibility is the observation that corticosteroids have a greater
effect on the number of T helper cells than cytotoxic suppressor
cells in systemic lupus erythematosus (SLE) patients [36] and in
CSA treated renal transplant patients (Hall et al, unpublished
data).
The mechanism of action of corticosteroids on the 18 and T4
mediated rejection response is not precisely defined, although it
is known that corticosteroids cause lymphocytopenia and
monocytopenia by inhibiting cell migration and inhibiting re-
lease of lymphokines from activated T cells [37], and as a
consequence have a profound effect on delayed-type hypersen-
sitivity cellular responses. Corticosteroids do inhibit the gener-
ation and cytolytic capacity of cytotoxic I cells in vitro [37, 38]
and thus would be expected to have some action on cytotoxic
cells in vivo. However, it cannot be excluded that cells already
infiltrating the graft are refractory to the effect of corticoster-
oids and that their sole effect is to inhibit migration of more
mononuclear cells into the graft. It has also been reported that
some T cell functions are relatively corticosteroid—resistant in
some patients and not others [39], and a similar variation in
responsiveness may occur for T4 and T8 mediated rejection.
Our studies suggest that the identification of a diffuse and
intense T cell infiltrate in which T8 cells predominate, and
which is associated with a glomerular T cell infiltrate, may
indicate a need for alternate rejection therapy. At present this
may be antithymocyte globulin. However, the use of monoclo-
nal antibodies with reactivity for one 1 cell subclass, such as
the T8 cells, also needs to be assessed.
Our observations failed to show that T4 and T8 cells react
against different HLA antigen classes in that neither was the
sole infiltrating subset in grafts mismatched for only Class I or
Class II MHC antigens. In the six grafts examined from patients
with no incompatibility for HLA A and B, the four that had
HLA-DR incompatibility only had 14 cells in the infiltrate,
which would be consistent with a T4 mediated response against
HLA-DR. The other two patients had no mismatches for
HLA-DR and these were the biopsies which had 18 cells in the
infiltrate, which would be consistent with the observation in
rodents that responses to non-MHC transplantation antigens
are usually mediated by cytotoxic 1 cells, rather than delayed-
type hypersensitivity responses [15]. A large number of cases
with no class I MHC incompatibilities need to be examined to
see if these trends are real.
In this study 14 cells often predominated in the infiltrate
during rejection and were always a major component of this
infiltrate. This differs from previous studies of renal transplant
rejection in which the 18 subpopulation was found to predom-
inate [16—18]. Part of the explanation for these differences may
be the different monoclonal antibodies used to identify the
helper/inducer subset. In this report 14 was used, which is
known to stain some monocytes and macrophages as well as the
helper/inducer subclass of I cells [40]. In the reports of Platt et
al [16] and Hancock et al [17, 18] the OKT4 reagent was used,
and this reagent has been shown to give less intense staining of
both the T cell subset and monocytes [19, 32]. The finding of
large numbers of T4 and 18 cells as well as monocytes and
macrophages during rejection episodes identifies all elements
required for the mediation of graft damage by delayed type
hypersensitivity and direct I cell cytotoxicity responses.
Whether these subpopulations include activated effector cells,
and the cells' specific reactivity against graft alloantigens, has
not been shown in these studies or other reported studies, and
has been very difficult to determine with the currently available
monoclonal antibodies. Thus the proportion of the infiltrate
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which has specific reactivity, compared to that which repre-
sents a nonspecific component, cannot be assessed. OKT1O
failed to stain any cells in the majority of specimens even in
nephrectomies and biopsies with severe rejection, and thus was
not found to be a suitable reagent with which to identify
activated T cells. 12 stained nearly all infiltrating cells in severe
rejection, as well as graft cells. This widespread expression of
HLA-DR antigens by all cells within the graft may reflect the
presence of lymphokines which indiscriminately induce expres-
sion of class II antigens on all cells within the graft, including
infiltrating cells and renal tubular cells. Experiments have
shown that cells with specificity not directed to the graft
antigens do accumulate in rejecting tissue, and similar non-
specific accumulation of cells is likely to occur in clinical
rejection episodes [40]. Alternatively, it may reflect the high
proportion of activated T cells and monocytes/macrophages in
the infiltrate. Distinguishing specific alloantigen reactive cells
from cells with no specific reactivity is not feasible without
monoclonal antibodies which react either against activated T
lymphoblasts or idiotypes of alloreactive T cells.
These studies did demonstrate that there was no difference in
the type of cellular infiltrate in patients immunosuppressed with
Cyclosporine compared to those immunosuppressed with
azathioprine, prednisone and antilymphocyte globulin, even
though Cyclosporine has a mechanism of immunosuppression
of the rejection response quite different from azathioprine and
ALO [41]. The distinction of rejection from nephrotoxicity in
CSA treated patients is often difficult, and we have previously
described the criteria we use to distinguish rejection [2]. The
only significant difference was the lower intensity of expression
of HLA-DR antigens on tubular epithelial cells in the CSA
treated patients compared to the AZA treated patients with
moderate rejection. This difference could not be accounted for
on clinical outcome by CSA toxicity being confused with
rejection. There was also no difference in the intensity of T cell
infiltrate in the CSA biopsies. It is known that induction of the
HLA-DR antigens on epithelial and endothelial cells is depen-
dent upon gamma interferon released by activated T cells
[42—44] and CSA has been shown to inhibit T cell production of
this lymphokine [45]. The smaller increase in expression of
HLA-DR antigens in the CSA treated patients may be due to
the effect CSA has on inhibiting release of lymphokines by
activated T cells [45].
The demonstration that tubular cells express class II MHC
antigens during rejection has several important implications.
First, T4 mediated responses are thought to be restricted to act
against cells carrying class II antigens [13, 14]. Thus in normal
renal tissue their potential targets would be restricted to
endothelial cells, dcndritic cells and some mesangial cells.
Because renal tubular cells acquire class II MHC antigens
during rejection, they also would be vulnerable to T4 effector
responses. Even in grafts where there is no HLA-DR incom-
patibility, there is increased expression of class II antigens. In
these circumstances the T4 response may be acting against
minor transplantation antigens, but to be effective the target
cells must also express the relevant class II antigen. It would
appear from these studies that expression of HLA-DR antigens
is an index of immune inflammation in the graft rather than
HLA incompatibility, in the same way as self tissue expresses
class II antigens in cell mediated immune responses such as
primary biliary cirrhosis and thyroiditis [43, 44]. A consequence
of this increased expression of class II antigens is that many
cells in the graft may acquire the capacity to act as antigen
presenting cells, and thus initiate a rejection response. Such
changes make attempts to reduce the immunogenicity of a graft
by removal of passenger leucocytes futile [46]. Whether or not
increased expression of class II MHC precedes or is a prereq-
uisite of T cell mediated cell destruction remains to be
answered.
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